Search filters

Authors whose works are in public domain in at least one jurisdiction

List of works by Paul G Ambrose

1388. Dose Discrimination for ASN100: Bridging from Rabbit Survival Data to Predicted Activity in Humans Using a Minimal Physiologically Based Pharmacokinetic (mPBPK) Model

article published in 2018

1408. Population Pharmacokinetic (PK) Model to Describe Epithelial Lining Fluid (ELF) Penetration of ASN-1 and ASN-2 after ASN100 Administration to Healthy Subjects

article by Scott A Van Wart et al published November 2018 in Open Forum Infectious Diseases

Antimicrobial safety: focus on fluoroquinolones

scientific article

Antimicrobial treatment guidelines for acute bacterial rhinosinusitis

scientific article published on January 2004

Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi

scientific article

Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci

scientific article published in February 2009

Clinical pharmacodynamics of quinolones

scientific article published on September 2003

Correction to: PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside

scientific article published on 14 February 2018

Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis

scientific article

Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies

scientific article

Extended-spectrum beta-lactamases and clinical outcomes: current data

scientific article published in April 2006

Frequentist and Bayesian Pharmacometric-Based Approaches To Facilitate Critically Needed New Antibiotic Development: Overcoming Lies, Damn Lies, and Statistics ⬇️

scientific article published on December 12, 2011

Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia

scientific article published on 27 July 2009

PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside

scientific article published on 28 March 2017

Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime

scientific article

Pharmacokinetic-Pharmacodynamic Analyses for Efficacy of Ceftaroline Fosamil in Patients with Community-Acquired Bacterial Pneumonia ⬇️

scientific article published on September 16, 2013

Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models

scientific article

Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections

scientific article

Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model

scientific article

Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients.

scientific article published on 26 February 2009

Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia

scientific article

Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae

scientific article published on 25 November 2013

Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose

scientific article

Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia

scientific article published on 3 October 2011

Pharmacological and Patient-Specific Response Determinants in Patients with Hospital-Acquired Pneumonia Treated with Tigecycline ⬇️

scientific article published on December 5, 2011

Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data

scientific article published on 27 April 2020

Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical Studies

scientific article published on 27 March 2019

Population Pharmacokinetics of Oseltamivir: Pediatrics through Geriatrics ⬇️

scientific article published on May 13, 2013

Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections

scientific article published on December 2004

Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community‐acquired bacterial pneumonia ⬇️

scientific article published on August 14, 2013

Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis

scientific article

Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model

scientific article

Tigecycline Population Pharmacokinetics in Patients with Community- or Hospital-Acquired Pneumonia ⬇️

scientific article published on October 4, 2010

Torsades de pointes associated with fluoroquinolones

scientific article

Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints

scientific article published in January 2009

Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis

scientific article

Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia

scientific article

Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem

scientific article

Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team

scientific article

Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains

scientific article

Paulina is supported by:

About Paulina

Help